ADMA Biologics, Inc. Aktie News

ADMA Biologics remains a Buy as Q3 results and 2026 guidance support a bullish long-term outlook. ADMA's Asceniv drives robust revenue and margin expansion, with 2026 revenue guided at $630M and EBITDA margin at 56%. Yield-enhanced manufacturing and facility expansion position ADMA for further growth, while SG-001 offers optionality beyond 2029.

ADMA Biologics, Inc. ( ADMA ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Adam Grossman - Co-Founder, President, CEO & Director Brad Tade - CFO & Treasurer Conference Call Participants Anthony Petrone - Mizuho Securities USA LLC, Research Division Rick Miller - Cantor Fitzgerald & Co., Research Division Gary Nachman - Raymond James & Associates, Inc., Research Divisi...

3Q 2025 Total Revenue of $134.2 Million, a 12% YoY Increase  3Q 2025 GAAP Net Income of $36.4 Million, a 1% YoY Increase 3Q 2025 Adjusted EBITDA (1) of $58.7 Million, a 29% YoY Increase 3Q 2025 Adjusted Net Income (2) of $38.9 Million, an 8% YoY Increase FDA Lot Release of First Yield-Enhanced Production Batches Positions ADMA for Margin Expansion Beginning in 4Q 2025 and Continuing Through 202...

California-based Palisades Investment Partners sold 398,647 shares of ADMA Biologics for an estimated $7.3 million in the third quarter. The transaction marked a full exit from ADMA, with Palisades reporting no ownership as of September 30.

RAMSEY, N.J. and BOCA RATON, Fla.

The biotech sector has underperformed the market for many years now, but there are reasons to be optimistic about this area of the market. Many biotech/biopharma stocks also make good covered call trade candidates due to the liquidity and lucrativeness of the option premiums against these equities. Stocks had their biggest decline last Friday since the first half of April due to escalating trad...

ADMA Biologics' earnings are surging due to higher plasma yield and a profitable shift toward premium IG brands, boosting margins. FDA approval of yield-enhancement technology increases finished IG output by 20%, driving efficiency and supporting ongoing revenue and margin growth. Expanded plasma sourcing and improved logistics de-risk supply, supporting long-term growth and simplifying distrib...

ADMA's growth remains centered on Asceniv, Bivigam, and NABI-HB. These are its main value drivers today. ADMA Biologics' recent Q2 report showed that the company is working on enhancing its plasma yields by over 20% in IG output. This should help them with margin expansion beginning in 2026. ADMA also reaffirmed its guidance for over $500 million in 2025 revenues and over $625 million by 2026. ...